Taiwan Biotech Market Insight
-
World-Class Healthcare System: Taiwan’s healthcare system, ranked the world’s top by Numbeo Health Care Index in 2025 for the seventh consecutive year, underpins its thriving biotechnology sector.
-
Steady Industry Growth: Taiwan’s biomedical industry is growing steadily at 2.32 %, generating A$38.7 billion in revenue in 2024. In addition, 147 biotech companies are listed or traded over-the-counter on the stock exchange, with a combined market value exceeding A$73.5 billion.
-
Strategic Government Commitment: The government is deeply committed to accelerating the sector. Key initiatives include the Biomedical Development Plan and new policy reforms designed to foster biomedicine clusters, attract global R&D and manufacturing partners, and leverage Taiwan's strengths in AI-driven drug discovery and smart medical devices.
-
Strategic Asia-Pacific Hub: Taiwan is positioning itself as a leader in new drug development, regenerative medicine, and supply chain integration in the Asia-Pacific region. The passage of the Dual Acts for Regenerative Medicine has strengthened its appeal to international pharmaceutical companies and CDMO players.
-
Emerging Opportunities in Clinical Trials and Regenerative Medicine: Taiwanese bio companies are actively seeking partnerships to license-in novel IP and expand their pipelines, creating opportunities for conducting clinical trials, especially in the field of precision and cell and gene therapy.
-
Deepening Australia-Taiwan Collaboration: Biotechnology remains a priority area for bilateral cooperation. Following the 2024 Science and Technology Cooperation Arrangement, industry engagement continues to thrive. In 2024, 21 Australian companies participated in BIO Asia-Taiwan in July, highlighting the strong interest and platform for future partnership.
-
Deepening Australia-Taiwan Collaboration: Biotechnology remains a priority area for bilateral cooperation. Following the 2024 Science and Technology Cooperation Arrangement, industry engagement continues to thrive. In 2025, 24 Australian companies participated in BIO Asia-Taiwan in July, highlighting the strong interest and platform for future partnership, while 20 Taiwanese biotech delegates joined in the AusBiotech in Melbourne in October.
